Timothy Barberich and Wayne Roe to Join Gemin X Board of Directors.
"We are pleased to welcome Mr. Barberich and Mr. Roe to our board of directors. Their arrival will provide Gemin X with a vast breadth of industry experience to draw upon as we continue to advance GX15-070, our lead compound, through clinical trials for the treatment of cancer," said Dan Giampuzzi, President and CEO of Gemin X. "We look forward to their contributions to the growth and success of Gemin X."
Since founding Sepracor in 1984, Mr. Barberich has led the company through its initial public offering and the spin-outs of four publicly traded companies, growing Sepracor into a successful pharmaceutical company with nearly $6 billion in market capitalization. In addition to his current positions with Sepracor, Mr. Barberich serves on the board of directors for BioSphere Medical Inc., Point Therapeutics Inc., and PhRMA, the Pharmaceutical Research and Manufacturers of America industry organization. Prior to founding Sepracor, Mr. Barberich held various marketing, sales and management positions at Millipore Corporation. He also held various project management and research scientist positions at American Cyanamid Company. Mr. Barberich holds a bachelor's degree in chemistry from King's College.
Mr. Roe is currently an independent consultant in the life sciences industry and serves on the Board of Directors for several pharmaceutical and medical device companies, including Aradigm Corporation, Ista Pharmaceuticals Inc., Aderis Pharmaceuticals Inc., Intrapace Inc. and Favrille Inc. He has also previously served as an advisor to the Congressional Office of Technology Assessment, the Institute of Medicine and the Health Care Financing Administration. Mr. Roe was Senior Vice President of Product Economics and Health Policy for United Therapeutics Inc.; founder and Chairman of Covance Health Economics and Outcomes Services Inc., a contract research and developmental services company; and President of Health Technology Associates, a pharmaceutical industry consulting firm. He earned M.A.s from the State University of New York and the University of Maryland and a B.A. from Union College.
Gemin X Biotechnologies Inc. specializes in the discovery and development of novel small-molecule cancer therapeutics based on the regulation of apoptosis, the body's natural ability to destroy injured or damaged cells. Gemin X's lead product, GX15-070, is a small molecule, pan-inhibitor of Bcl-2 proteins. Gemin X is also developing small molecules that induce apoptosis in p53-defective cancers. Gemin X is privately held and is located in Montreal, Quebec and Malvern, Pennsylvania. For additional information please visit Gemin X at www.geminx.com
|Printer friendly Cite/link Email Feedback|
|Date:||Aug 8, 2005|
|Previous Article:||SightSpeed Partners with RemotePipes, Leading Provider of Roaming Internet Access Solutions.|
|Next Article:||SigmaQuest's SigmaExpress Product Performances Intelligence and Quality Management System Eliminates the Need for Desktop Test Data Management Tools,...|
|CHANGES IN BOARD STAFF.|
|New team prepares to lead TEI. (Recent Activities).|
|NY Real Estate Managers complete annual elections.|
|Changes in board staff.|